Atillasoy Ercem's Form 4/A amendment

Amended

Kalaris Therapeutics, Inc. (KLRS) · filed Oct 26, 2022

Accession no.: 0000899243-22-034264
Filed: Oct 26, 2022
Trade date: Oct 20-21, 2022
Filing delay: 6 days
Rule 10b5-1 plan: Not on the form (before 2023)
Original filed: Oct 24, 2022

Original on SEC EDGAR (opens in a new tab)

This filing lists 2 non-derivative transactions. Open-market sales total $18.3K. It was filed 6 days after the trade.

This amendment replaces 0000899243-22-034054 (filed Oct 24, 2022).

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
Owner	Relationship to the company
Atillasoy ErcemCIK 0001818802	Officer (See Remarks)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade date	Security	Transaction	Shares	Price	Value	Shares after	Ownership	Flags
Oct 20, 2022	Common Stock	SSaleDisposed	−568	$9.36^F2	−$5,316.48	132,899	Direct
Oct 21, 2022	Common Stock	SSaleDisposed	−1,527	$8.48^F3	−$12,948.96	131,372	Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units, and does not represent a discretionary trade by the Reporting Person.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $9.08 to $9.72. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $8.40 to $8.61. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.

Referenced by the price of 1 transaction in Table I.

Remarks

This Form 4/A is being filed correct the transaction dates reported in the original Form 4 filed on October 24, 2022. Officer Title: Chief Regulatory and Safety Officer

Read the full filing on SEC EDGAR (opens in a new tab)